PITTSBORO, NC--(Marketwire - November 06, 2007) - Biolex Therapeutics, Inc. today announced that the results from its SELECT-1 Phase 2a clinical trial of Locteron™ will be presented today at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). SELECT-1 was a twelve-week trial designed to evaluate four doses of Locteron administered once every two weeks in combination with the antiviral drug ribavirin. Viral kinetic modeling of the SELECT-1 results by Eva Herrmann, Ph.D. and Stefan Zeuzem, M.D. of Saarland University Hospital, Homburg/Saar, Germany, demonstrated a statistically significant dose response. The study results also suggested that patients receiving Locteron experienced side effects that were less frequent and less severe than those previously reported in clinical trials for the currently marketed pegylated interferons and for Albuferon®, a product candidate currently under development. Biolex is co-developing Locteron with its partner OctoPlus N.V.
